NASDAQ · CMPS
COMPASS Pathways plc
$12.19-$0.09 (-0.73%)
COMPASS Pathways plc’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
Loading market information…
NASDAQ · CLPT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ClearPoint Neuro, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.21% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ClearPoint Neuro, Inc.’s next earnings report is currently expected on Mar 3, 2027, with estimated earnings per share of -$0.29. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ClearPoint Neuro, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Aug 12, 2025 | -$0.21-5.0% vs estimate | $9.22M-5.97% vs estimate |
|---|
| Q1 2025 | May 13, 2025 | -$0.22-46.67% vs estimate | $8.49M-7.44% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | -$0.20-33.33% vs estimate | $7.77M-5.57% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $21.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$12.19-$0.09 (-0.73%)
COMPASS Pathways plc’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
$24.99+$0.01 (+0.04%)
Avanos Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
$22.41+$0.58 (+2.66%)
SI-BONE, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.35% below the high.
$6.30+$0.16 (+2.61%)
Cytek Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$18.44-$0.01 (-0.05%)
Varex Imaging Corporation’s quoted price sits in the upper half of its reported 52-week range, 1.02% below the high.
$42.98+$0.15 (+0.35%)
Surmodics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.06% below the high.
$10.24+$0.20 (+1.99%)
Orthofix Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.73% below the high.
$1.30+$0.01 (+0.78%)
SNDL Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
